RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors

RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors

DNA damaging chemotherapy is a cornerstone of current front‐line treatments for advanced ovarian cancer (OC). Despite the fact that a majority of these patients initially respond to therapy, most will relapse with chemo‐resistant disease; therefore, adjuvant treatments that synergize with DNA‐damagi...

Full description

Bibliographic Details
Main Authors: Dreaden, Erik (Contributor), Kong, Yi Wen (Contributor), Quadir, Mohiuddin Abdul (Contributor), Correa Echavarria, Santiago (Contributor), Suarez Lopez, Lucia (Contributor), Barberio, Antonio Eric (Contributor), Hwang, Mun Kyung (Contributor), Shi, Aria C. (Contributor), Oberlton, Benjamin J. (Contributor), Gallagher, Paige N. (Contributor), Shopsowitz, Kevin (Contributor), Elias, Kevin (Contributor), Yaffe, Michael B (Contributor), Hammond, Paula T (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Wiley, 2018-07-13T16:53:21Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items